Research Analysts Offer Predictions for ESLA Q2 Earnings

Estrella Immunopharma, Inc. (NASDAQ:ESLA) – Equities researchers at Zacks Research issued their Q2 2026 earnings estimates for Estrella Immunopharma in a report released on Tuesday, July 14th. Zacks Research analyst D. Bautz expects that the company will post earnings per share of ($0.09) for the quarter. The consensus estimate for Estrella Immunopharma’s current full-year earnings is ($0.39) per share. Zacks Research also issued estimates for Estrella Immunopharma’s Q3 2026 earnings at ($0.08) EPS, Q4 2026 earnings at ($0.07) EPS and FY2026 earnings at ($0.29) EPS.

Separately, Weiss Ratings upgraded Estrella Immunopharma from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, June 12th. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $8.00.

Estrella Immunopharma Trading Down 3.8%

Shares of NASDAQ ESLA opened at $0.74 on Friday. The company has a 50 day simple moving average of $1.05 and a two-hundred day simple moving average of $1.20. The stock has a market cap of $31.93 million, a price-to-earnings ratio of -2.18 and a beta of 0.85. Estrella Immunopharma has a 12 month low of $0.73 and a 12 month high of $3.15.

Estrella Immunopharma (NASDAQ:ESLA) last released its earnings results on Saturday, May 16th. The company reported ($0.05) earnings per share for the quarter, topping the consensus estimate of ($0.08) by $0.03.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ESLA. Renaissance Technologies LLC lifted its stake in shares of Estrella Immunopharma by 1,045.7% in the fourth quarter. Renaissance Technologies LLC now owns 122,468 shares of the company’s stock worth $191,000 after buying an additional 111,779 shares in the last quarter. Geode Capital Management LLC grew its stake in Estrella Immunopharma by 8.2% during the 4th quarter. Geode Capital Management LLC now owns 109,808 shares of the company’s stock valued at $171,000 after acquiring an additional 8,318 shares in the last quarter. Marshall Wace LLP acquired a new stake in Estrella Immunopharma in the 4th quarter valued at about $88,000. XTX Topco Ltd raised its holdings in Estrella Immunopharma by 376.9% in the 4th quarter. XTX Topco Ltd now owns 49,472 shares of the company’s stock valued at $77,000 after acquiring an additional 39,099 shares during the last quarter. Finally, State Street Corp lifted its stake in Estrella Immunopharma by 93.5% in the 4th quarter. State Street Corp now owns 43,252 shares of the company’s stock worth $67,000 after purchasing an additional 20,900 shares in the last quarter. Hedge funds and other institutional investors own 0.35% of the company’s stock.

About Estrella Immunopharma

Estrella Immunopharma, Inc, a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103.